Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1638-1649

  Catanzaro, Andrew T ^a   Koup, Richard A ^a   Roederer, Mario ^a   Bailer, Robert T ^a   Enama, Mary E ^a   Moodie, Zoe ^c   Gu, Lin ^c   Martin, Julie E ^a   Novik, Laura ^a   Chakrabarti, Bimal K ^a   Butman, Bryan T ^b   Gall, Jason G D ^b   King, C Richter ^b   Andrews, Charla A ^a   Sheets, Rebecca ^a   Gomez, Phillip L ^a   Mascola, John R ^a   Nabel, Gary J ^a   Graham, Barney S ^a   Larkin, Brenda ^a   McCluskey, Margaret ^a   Hubka, Sarah ^a   Holman, LaSonji ^a   Gordon, Ingelise ^a   Edmonds, Pamela ^a   Rucker, Steve ^a   Parrino, Janie ^a   Casazza, Joseph ^a   Fix, Alan ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENVEC INC   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; PLACEBO; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VRC HIVADV014 00 VP;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS VECTOR; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEROTYPE; SIDE EFFECT; STEATORRHEA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NAUSEA; RECOMBINATION, GENETIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 33845439080     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509258     Document Type: Article

References (40)

1. UNAIDS/WHO. AIDS epidemic update: December 2005. Geneva: UNAIDS, 2005.
2. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005; 16:149-56.
3. Clark KR, Johnson PR. Gene delivery of vaccines for infectious disease. Curr Opin Mol Ther 2001; 3:375-84.
4. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann Rev Med 2004;55:355-72.
5. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
6. Casimiro DR, Tang A, Chen L, et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:7663-8.
7. Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005; 79:771-9.
8. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
9. Sullivan NJ, Geisbert TW, Geisbert JH, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates. Nature 2003; 424:681-4.
10. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190-7.
11. Nabel G, Makgoba W, Esparza J. HIV-1 diversity and vaccine development. Science 2002;296:2335.
12. Huang Y, Kong WP, Nabel GJ. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 2001; 75:4947-51.
13. Chakrabarti BK, Kong WP, Wu BY, et al. Modifications of human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76:5357-68.
14. Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9:951-7.
15. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70:6497-501.
16. Butman BT, Lizonova A, Brough DE, et al. Comprehensive characterization of the 293-ORF6 cell line. In: Petricciani J, Sheets R, eds. Vaccine cell substrates 2004: developments in biologicals. Vol. 123. Rockville, MD: Karger, 2006:225-33.
17. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-60 (in this issue).
18. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25.
19. Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41:5046-52.
20. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 2006; 315:121-32.
21. Bruna-Romero O, Schmieg J, Del Val M, Buschle M, Tsuji M. The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria. J Immunol 2003; 170:3195-203.
22. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13:15-63.
23. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocytc activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
24. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
25. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994; 370:463-7.
26. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997; 185:293-303.
27. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
28. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
29. Yang O, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996; 70:5799-806.
30. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressons and long-term asymptomatics. J Exp Med 1995; 181:1365-72.
31. Moss PA, Rowland-Jones SL, Frodsham PM, et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995;92: 5773-7.
32. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-60.
33. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-8.
34. Nixon DF, Townsend AR, Elvin JG, Rixza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptidcs. Nature 1988; 330:484-7.
35. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of virema [see comments]. Science 1997; 278:1447-50.
36. + T cell proliferation. Proc Natl Acad Sci USA 2001;98:13878-83.
37. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, et al. Lymphoproliterative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses 1999; 15:973-81.
38. Barouch DH, Kunstman J, Glowczwskie J, et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-75.
39. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-6.
40. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. 1 Virol 2003; 77:6305-13.